Evoke Pharma (EVOK) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
Evoke Pharma (NASDAQ:EVOK) issued its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01), Bloomberg Earnings reports.
Shares of EVOK opened at $2.74 on Wednesday. The firm has a market capitalization of $46.47 million, a P/E ratio of -3.30 and a beta of 1.66. Evoke Pharma has a one year low of $1.85 and a one year high of $3.40.
In related news, major shareholder Lvp Gp Iii, Llc bought 500,000 shares of the stock in a transaction that occurred on Monday, August 20th. The shares were bought at an average cost of $2.35 per share, for a total transaction of $1,175,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 11.94% of the stock is currently owned by insiders.
EVOK has been the subject of several research analyst reports. ValuEngine raised Evoke Pharma from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. HC Wainwright set a $9.00 price objective on Evoke Pharma and gave the stock a “buy” rating in a report on Friday, August 17th. Finally, Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Friday, August 17th.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Recommended Story: Dividend Aristocrat Index
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.